SOHO 2020: Elevated LDH Levels and Overall Survival in AML
Posted: Thursday, September 24, 2020
According to research presented at the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract AML-029), elevated lactate dehydrogenase (LDH) levels in patients with acute myeloid leukemia (AML) may be associated with poor survival outcomes. Mohamed Mabed, MD, PhD, of Mansoura University in Egypt, and colleagues noted that the tumor burden activity associated with elevated LDH levels often resulted in a poor prognosis for patients with other malignancies, including acute leukemias.
The observational, single-center study was conducted from October 2016 to 2017 and included 40 patients with de novo AML and 10 healthy control participants. At the time of enrollment, the FAB classification of each patient with AML was noted (M1, 20%; M2, 25%; M4, 32.5%; M5, 17.5%; M6, 5%). The majority of patients (n = 33, 85%) had an intermediate risk, whereas 4 patients had a favorable risk and 3 patients had an unfavorable risk. Approximately half of the patients were female.
Almost all patients (39 of 40) were found to have significantly elevated LDH levels, with a median LDH level of 731.5 U/L. Patients with high LDH levels were found to have shorter 1-year overall survival than those without elevated LDH levels. Overall survival was predicted using Cox regression analysis, and this finding was confirmed in univariate (P = .018, hazard ratio [HR] = 1.012, 95% confidence interval [CI] = 1.005–1.0710) and multivariate (P = .031, HR = 1.023, 95% CI = 1.002–1.091) analyses. At the end of the study, 11 patients remained alive.
Disclosure: Disclosures of the study authors were not provided.